MedPath

Nadolol

Generic Name
Nadolol
Brand Names
Corgard
Drug Type
Small Molecule
Chemical Formula
C17H27NO4
CAS Number
42200-33-9
Unique Ingredient Identifier
FEN504330V
Background

Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects.

Nadolol was granted FDA approval on 10 December 1979.

Indication

Nadolol is indicated to treat angina pectoris and hypertension. Another product formulated with bendroflumethiazide is indicated to treat hypertension.

Associated Conditions
Angina Pectoris, Atrial Fibrillation, Gastroesophageal variceal hemorrhage prophylaxis, Hypertension, Migraine, Thyrotoxicosis
Clinical Trials
Related News

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Early Phase 1
Recruiting
Conditions
Leukemia
Hematopoetic Stem Cell Transplantation
Donor Lymphocyte Infusion
CAR T-Cell Therapy
Lymphoma
Cell Therapy
Interventions
Behavioral: Exercise
Drug: Placebo
First Posted Date
2024-10-16
Last Posted Date
2024-10-16
Lead Sponsor
University of Arizona
Target Recruit Count
100
Registration Number
NCT06643221
Locations
🇺🇸

The University of Arizona, Tucson, Arizona, United States

Study of INV-102 Ophthalmic Solution in Adults With Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy

Phase 2
Recruiting
Conditions
Non-center Involved Diabetic Macular Edema
Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Diabetic Retinopathy
Center-involved Diabetic Macular Edema
Center-involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy
Interventions
First Posted Date
2024-09-19
Last Posted Date
2025-04-24
Lead Sponsor
Invirsa, Inc.
Target Recruit Count
24
Registration Number
NCT06599684
Locations
🇺🇸

MedTrials, Inc., Dallas, Texas, United States

Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease

Phase 2
Completed
Conditions
Dry Eye Disease
Interventions
Drug: Vehicle
First Posted Date
2024-04-17
Last Posted Date
2024-07-12
Lead Sponsor
Invirsa, Inc.
Target Recruit Count
109
Registration Number
NCT06370039
Locations
🇺🇸

iuvo BioScience, Rush, New York, United States

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

Phase 2
Recruiting
Conditions
Acute Infectious Keratoconjunctivitis
Interventions
Drug: Vehicle
First Posted Date
2022-12-05
Last Posted Date
2024-05-16
Lead Sponsor
Invirsa, Inc.
Target Recruit Count
102
Registration Number
NCT05636228
Locations
🇺🇸

Global Research Management, Glendale, California, United States

🇺🇸

Foothill Eye Institute, Pasadena, California, United States

🇺🇸

Shettle Eye Research, Largo, Florida, United States

and more 9 locations

Study of INV-102 Ophthalmic Solution in Adults With Moderate Symptomatic Dry Eye Disease

Phase 1
Completed
Conditions
Dry Eye Disease
Interventions
Drug: Vehicle
First Posted Date
2022-10-19
Last Posted Date
2024-04-10
Lead Sponsor
Invirsa, Inc.
Target Recruit Count
84
Registration Number
NCT05586152
Locations
🇺🇸

iuvo BioScience, Rush, New York, United States

Nadolol Versus Propranolol in Children With Infantile Hemangiomas

Phase 3
Completed
Conditions
Infantile Hemangioma
Interventions
First Posted Date
2015-07-22
Last Posted Date
2020-10-28
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
74
Registration Number
NCT02505971
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

Efficacy and Safety of Î’eta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

Phase 2
Completed
Conditions
Smoking Cessation
Interventions
Drug: Placebo
First Posted Date
2013-04-05
Last Posted Date
2017-02-01
Lead Sponsor
Invion, Inc.
Target Recruit Count
155
Registration Number
NCT01825122
Locations
🇺🇸

Nuren Medical, Miami, Florida, United States

🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

🇺🇸

Abel Buchheim Pharmaceutical Research, Miami, Florida, United States

and more 1 locations

Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma

Phase 2
Conditions
Mild Persistent Asthma, Uncomplicated
Interventions
Drug: Placebo
First Posted Date
2013-03-05
Last Posted Date
2016-08-09
Lead Sponsor
Invion, Inc.
Target Recruit Count
60
Registration Number
NCT01804218
Locations
🇺🇸

Washington University School of Medicine, St. Louis, Missouri, United States

🇺🇸

Baylor College of Medicine, Houston, Texas, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

A Trial of Nadolol Plus Isosorbide Mononitrate Versus Carvedilol for the Prevention of Variceal Rebleeding

Phase 4
Completed
Conditions
Variceal Rebleeding
Interventions
First Posted Date
2010-04-14
Last Posted Date
2010-10-26
Lead Sponsor
E-DA Hospital
Target Recruit Count
121
Registration Number
NCT01103154

Nadolol for Proliferating Infantile Hemangiomas

Phase 2
Completed
Conditions
Infantile Hemangioma
Interventions
First Posted Date
2009-11-10
Last Posted Date
2021-08-19
Lead Sponsor
The Hospital for Sick Children
Target Recruit Count
20
Registration Number
NCT01010308
Locations
🇨🇦

The Hospital for Sick Children, Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy